Exploiting the PI3K/AKT pathway for cancer drug discovery

Bryan T. Hennessy, Debra L. Smith, Prahlad T. Ram, Yiling Lu, Gordon B. Mills

    Research output: Contribution to journalReview articlepeer-review

    1573 Scopus citations


    Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

    Original languageEnglish (US)
    Pages (from-to)988-1004
    Number of pages17
    JournalNature Reviews Drug Discovery
    Issue number12
    StatePublished - Dec 2005

    ASJC Scopus subject areas

    • Pharmacology
    • Drug Discovery

    Fingerprint Dive into the research topics of 'Exploiting the PI3K/AKT pathway for cancer drug discovery'. Together they form a unique fingerprint.

    Cite this